Clinical Trials Browser

Phase 3 × Interventional × aclacinomycins × Clear all

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute